ArticleJournal of molecular neuroscience : MN2026
Integrated Bioinformatics and in vivo Validation Identify the MTRNR2L1/MTRNR2L10 Axis as a Candidate Regulator Associated with Cortical NLRP3 Inflammasome-Related Signaling in Experimental Epilepsy.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The mechanisms underlying seizure-induced cortical injury in status epilepticus-related experimental epilepsy remain incompletely understood, and upstream regulators of inflammasome activation require further clarification. By combining bioinformatics screening with in vivo validation, we examined whether the MTRNR2L1/MTRNR2L10 axis is associated with NLRP3 inflammasome-related signaling in the cerebral cortex of rats subjected to status epilepticus, with the goal of identifying candidate regulators of seizure-induced cortical injury. The GSE134697 dataset was obtained from GEO. Differentially expressed genes (DEGs) were screened using |log2FC|>4 and adjusted P < 0.05. GO/KEGG enrichment analyses, together with a STRING-based protein-protein interaction (PPI) network, prioritized MTRNR2L1/MTRNR2L10 as candidate molecules annotated to the "regulation of signal transduction" pathway for subsequent in vivo validation. Ninety SPF SD rats (10 per group) were used: a basic model module (normal, sham, and EP model) and a target-intervention module (six groups: negative control, overexpression, and knockdown for MTRNR2L1/MTRNR2L10). Behavioral scoring, histopathology, Western blotting, co-immunoprecipitation, and ELISA were performed. Fifty-one DEGs were identified. Among them, only MTRNR2L1/MTRNR2L10 mapped to signal-transduction regulation associated with EP, and their cortical expression in EP rats fell to < 30% of control. Upregulating this axis lowered Racine seizure scores and neurological deficit scores, was associated with reduced NLRP3 inflammasome-related marker expression, mitigated the loss of BBB-related tight-junction protein markers, and reduced cortical neuronal apoptosis. In contrast, silencing either target exacerbated these changes, and co-immunoprecipitation suggested that the two molecules were associated within the same protein complex. The MTRNR2L1/MTRNR2L10 axis may act as a candidate protective regulator in status epilepticus-related experimental epilepsy, in association with reduced NLRP3 inflammasome-related signaling. These findings support further mechanistic evaluation of MTRNR2L1/MTRNR2L10 in seizure-induced cortical injury, but do not establish these molecules as therapeutic targets for drug-resistant epilepsy.
Indexed as
Identifiers
42289503What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.